TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01215227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: Daily for 40 weeks: 2, 5, or 10 mg preladenant tablet each morning; 2, 5, or 10 mg preladenant tablet each evening (approximately 8 hours after the morning dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rasagiline
Description: Daily for 40 weeks: 1 mg rasagiline capsule each morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rasagiline
Description: Daily for 40 weeks: 1 mg rasagiline capsule each morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to preladenant
Description: Placebo to match preladenant given daily for 40 weeks: placebo tablet each morning; placebo tablet each evening (approximately 8 hours after the morning dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to preladenant
Description: Placebo to match preladenant given daily for 40 weeks: placebo tablet each morning; placebo tablet each evening (approximately 8 hours after the morning dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to rasagiline
Description: Placebo to match rasagiline given daily for 40 weeks: placebo capsule each morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to rasagiline
Description: Placebo to match rasagiline given daily for 40 weeks: placebo capsule each morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to rasagiline
Description: Placebo to match rasagiline given daily for 40 weeks: placebo capsule each morning
Study: NCT03419728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Families, Healthy Futures
Description: Home visiting program for pregnant and parenting teens
Study: NCT02769221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rigid video stylet

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video laryngoscope
Study: NCT02779413

Intervention type: DRUG
Intervention: insulin degludec
Description: Patients will be treated with commercially available Tresiba® FlexTouch® according to routine clinical practice at the discretion of the treating physician.
Study: NCT04186338

Intervention type: DEVICE
Intervention: Omnidirectional accelerometer monitor (3x3 cm and 16 g, Actical®, Philips Respironics)
Description: All participants were instructed to wear monitors for five consecutive days except during water-based activities. Data for each participant was collected to ensure included three valid weekdays. Daily activity energy expenditure (kcal/kg/min), and sedentary, light, moderate and vigorous levels (min) were examined using a software program.

Intervention type: DEVICE
Intervention: Omnidirectional accelerometer monitor (3x3 cm and 16 g, Actical®, Philips Respironics)
Description: All participants were instructed to wear monitors for five consecutive days except during water-based activities. Data for each participant was collected to ensure included three valid weekdays. Daily activity energy expenditure (kcal/kg/min), and sedentary, light, moderate and vigorous levels (min) were examined using a software program.
Study: NCT03731247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCTAV Patient
Description: In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
Study: NCT00419198

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postconditioning
Description: Postconditioning during angioplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard angioplasty
Description: standard angioplasty without postconditioning
Study: NCT01398956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: formulation: tablet or dry syrup~strength: 250 mg tablet, 500 mg tablet, dry syrup 50%~dosage: Sb ≥16 years and ≥4 and \<16 years (≥50 kg): 1000 mg/day, 2000 mg/day or 3000 mg/day; Sb ≥4 and \<16 years (\<50kg): 20 mg/kg/day, 40 mg/kg/day, or 60 mg/kg/day~frequency: twice daily
Study: NCT02956733

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dermotaxis
Description: In dermotaxis (Singhs skin traction) method two parallel kirschner wires (1.5mm) will be passed through the dermis on either side of the wound margins and interconnected by compression device consisting of threaded rod having two blocks and compression knob. Gradual compression will be applied daily at the rate of 1 turn/12hours on both sides of the wound.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: loop suture technique
Description: The loop suture technique involves using corrugated drains and Ethilon no.1. It is an extension of the purse string suture technique where a surgical suture is passed as a running stitch in and out along the edge of a wound in such a way that when the ends of the suture are drawn tight the wound is closed. Two corrugated drains (1 \& 2) will be anchored to the skin adjacent to the fasciotomy incision using Ethilon no.1. Then the sutures will be passed from one edge of the wound through the skin and corrugated drain to the other in an alternating fashion.
Study: NCT02071524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group Colloid
Description: Group Colloid: cristalloid 1:2 (gelofusine: ringer lactate)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cristalloid administration
Description: Only Ringer Lactate administration
Study: NCT00856908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Tolerable dose given twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tolerable dose given twice daily
Study: NCT01667978

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Norethindrone acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone acetate
Study: NCT04407130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin + Doxycycline + Placebo
Description: Arm I: 200 mcg/kg (12 mg tablet) ivermectin (IVERA) single dose and 200 mg stat doxycycline day-1 followed by 100mg doxycycline 12hrly for 4 day (i.e. day2-day5)~Placebo one tablet D2-5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin + Placebo
Description: Arm II: Ivermectin - 200 mcg/kg (12 mg tablet) once per day D1-D5 + Placebo two tablets D1 followed by Placebo one tablet D2-5

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm III: 3 Placebo tablets D1 followed by 2 tablets D2-5
Study: NCT03569228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study 1 - ITE hearing aids
Description: Experienced users of in-the-ear (ITE) hearing aids will receive replacement ITE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study 1 - BTE hearing aids
Description: Experienced users of behind-the-ear (BTE) hearing aids will receive replacement BTE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Study 3 (open-fit comparison)
Description: This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling using the standard of care approach, then undergoing a 4-week field trial.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Study 3 (closed-fit comparison)
Description: This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling using the standard of care approach, then undergoing a 4-week field trial.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study 3 (experimental open-fit)
Description: Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study 3 (experimental closed-fit)
Description: Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
Study: NCT01063595

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octaplas LG
Description: Octaplas LG was composed of human coagulation-active plasma treated with solvent/detergent for 1-1.5 hours to remove enveloped viruses, eg, HIV, HBV, and HCV. An additional manufacturing step, involving an affinity ligand gel, removed prion proteins. Octaplas LG was provided frozen in pyrogen free plastic bags.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Octaplas SD
Description: Octaplas SD was composed of human coagulation-active plasma treated with solvent/detergent for 4-4.5 hours to remove enveloped viruses, eg, HIV, HBV, and HCV. Octaplas SD was provided frozen in pyrogen free plastic bags.
Study: NCT03389464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computer-based confrontation with dysfunctional beliefs
Description: Patients will be presented with a virtual agent confronting them with their dysfunctional core beliefs (e.g. You are worthless). Participants will be instructed to contradict these virtual agents (e.g. That's not true, I'm a wonderful person).
Study: NCT04118309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00451035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Study: NCT03119415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooperative Learning
Description: CL is an umbrella term that includes peer tutoring, reciprocal teaching, collaborative reading, and other methods in which peers help each other learn in small groups. CL is not prescriptive but rather is a conceptual framework within which teachers design their own small-group activities. Johnson, Johnson, and Holubec's approach to CL combines positive interdependence with individual accountability, a high degree of face-to-face social interaction among youth, and support for the development of cooperative social skills. The Johnsons' approach offers teachers the combination of specific cooperative activities and the conceptual tools to create their own lesson plans using positive interdependence.
Study: NCT01070316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus is available in tablet form. The starting dose will be 5 mg/m2/day, rounded to the nearest 2.5 mg/dose, to be taken daily. After two weeks, serum trough level will be measured and dose adjusted according to the following algorithm If Blood trough level is less than 2.5 ng/ml than increase dose by 5 mg/m2/day; If Blood trough level is 2.5-5.0 ng/ml than increase dose by 2.5 mg/m2/day; If Blood trough level is 5.1-10.0 ng/ml than increase dose by 0 mg/m2/day (no change); If Blood trough level is 10.1-15.0 ng/ml than decrease dose by 2.5 mg/m2/day
Study: NCT01365390

Intervention type: OTHER
Intervention: Data collection (Retrospective)
Description: For the retrospective part of the study, the parent(s)/ legally acceptable representative(s) of the subjects will be interviewed to collect information on factors potentially related to risk for middle ear diseases. The medical records of the subjects will also be reviewed and all acute otitis media related problems that occurred during the last year prior to enrolment (for subjects aged 1 to \< 6 years) or since birth (for subjects aged \< 1 year) will be recorded in the electronic case report form.

Intervention type: OTHER
Intervention: Data collection (Prospective)
Description: For the prospective part of the study, the enrolled subjects will be followed up for a period of 1 year starting from the consent date, during which the parent(s)/ legally acceptable representative(s) will be asked to bring the subject for a visit each time they notice symptoms of acute otitis media or respiratory tract infection in the subject. In case AOM is diagnosed by the investigator, detailed information on the signs, symptoms, severity, course and treatment will be recorded. The parent(s)/ legally acceptable representative(s) of the subjects will also be required to fill up a parental quality of life questionnaire and an Otitis Media-6 children's quality of life questionnaire.
Study: NCT02531321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel and Ethinyl Estradiol
Description: All participants will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days. Pharmacokinetics and pharmacodynamics will be compared between participants using antiretroviral regimens including ritonavir-boosted protease inhibitors and those using regimens that do not interact with oral contraceptives.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel and Ethinyl Estradiol
Description: All participants will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days. Pharmacokinetics and pharmacodynamics will be compared between participants using antiretroviral regimens including ritonavir-boosted protease inhibitors and those using regimens that do not interact with oral contraceptives.
Study: NCT03561493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: zumba exercise
Description: Participants will engage in 16 classes of 60-minute Zumba® fitness for two consecutive menstrual cycles (an 8-week period, twice weekly). Each class was one hour in length and a recovery period of at least 48 h was taken between classes. Each session will be initiated with low-intensity movements for the ﬁrst 5 min, followed by an increasing intensity throughout the workout. At the end of the training session, the intensity will be gradually reduced. The Zumba sessions will be supervised by three certiﬁed Zumba instructors, each responsible for regular sessions per week.
Study: NCT02265978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CopeSmart
Description: Participants will use the CopeSmart app at least once per day for four weeks
Study: NCT02439216

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01232452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Administered IV
Study: NCT03655730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weekly psychotherapeutic individual sessions
Description: weekly psychotherapeutic individual sessions following the IPT method during one year

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: the standard follow-up provided by the Mission Locale, including periodic meetings with a referee

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: the standard follow-up provided by the Mission Locale, including periodic meetings with a referee
Study: NCT01625091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: The study involves taking the drug naltrexone for up to 4 months. This will be given in a single pill each day for 4 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is an inert pill that looks the same as naltrexone. The placebo will be taken once each day for up to 4 months.
Study: NCT04163965

Intervention type: DEVICE
Group type: OTHER
Intervention: Capacitive ECG
Description: Patients having a pacemaker will sit down on a seat bearing capacitive ECG electrodes during their routine heart checkup at the cardiology.
Study: NCT01933867

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Water immersion
Description: Water immersion means infusion of room temperature water during colonoscope insertion without air insufflation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Air insufflation insertion
Study: NCT03214627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anemia Control Model (ACM)
Description: The ACM is mainly composed of 2 sub-Systems - predictor model which, depending on the input data, forecasts the response to anaemia drug therapy for a specific patient. The predictor model is implemented as a feed-forward artificial neural network. The ACM is an algorithm that extracts the optimal policy to achieve the established clinical outcome for anaemia management using the predictor model.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV iron
Description: IV iron given monthly as required - dose determined by the ACM and as agreed by the investigator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoiesis-Stimulating Agent (ESA)
Description: ESA given monthly as required over 6 months - dose determined by the ACM and as agreed by the investigator
Study: NCT03731247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCTAV Control group
Description: In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
Study: NCT00003968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1
Study: NCT01059318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus was formulated as tablets in strengths of 2.5mg, 5mg and 10mg.
Study: NCT00681928

Intervention type: DRUG
Intervention: anastrozole
Description: As determined by the subject's physician

Intervention type: DRUG
Intervention: letrozole
Description: As determined by the subject's physician

Intervention type: OTHER
Intervention: questionnaire administration
Description: For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.

Intervention type: OTHER
Intervention: questionnaire administration
Description: For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.

Intervention type: PROCEDURE
Intervention: cognitive assessment
Description: For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.

Intervention type: PROCEDURE
Intervention: cognitive assessment
Description: For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.

Intervention type: PROCEDURE
Intervention: psychosocial assessment and care
Description: For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.

Intervention type: PROCEDURE
Intervention: psychosocial assessment and care
Description: For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
Study: NCT04649684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional robot-assisted gait training
Description: They got conventional robot-assisted gait training, guidance force given equally to both limbs, and then gradually reduce the degree of guidance force to the extent that the patient is tolerable equally .during 4- week treatment session

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lower CIMT robot-assisted gait training group
Description: They got robot-assisted gait training based on CIMT concept; 100% guidance force is given on the unaffected side and then verbal ques are given not to contract unaffected muscle voluntarily as much as possible are provided, automatically according to the predetermined joint trajectory. In contrast at the affected side, gradually reduce the degree of guidance force to the extent that the patient is tolerable.
Study: NCT01441323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Nutrition classes for 1 hour \& 30 minutes once a week for 16 weeks + motivational interviewing (4 individual sessions)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength Training & Nutrition
Description: Strength Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour \& 30 minutes for 16 weeks + motivational interviewing (4 individual \& 4 group sessions)
Study: NCT02133092

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.
Study: NCT04386694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active PBMT/sMF
Description: The PBMT/sMF will be irradiated in the lower thorax and neck areas, with the patients in supine position. PBMT/sMF application time will be 60 seconds per site. The dose used in the lower thorax will be 31.50 J per site, a total of 6 sites will be irradiated, totalizing a dose of 189J. In addition, the dose used in the neck area (bilaterally) will be 31.50J per site, a total of 1 site (bilaterally) will be irradiated, totalizing a dose of 31.50J (bilaterally). PBMT/sMF will be applied using the direct contact method with light pressure on the skin.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PBMT/sMF
Description: The placebo PBMT/sMF will be irradiated in the lower thorax and neck areas, with the patients in supine position. PBMT/sMF application time will be 60 seconds per site. The dose used for applications during the treatment will be 0 Joules (J) per site. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). PBMT/sMF will be applied using the direct contact method with light pressure on the skin.
Study: NCT02197091

Intervention type: OTHER
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Intervention: medical chart review
Description: Ancillary studies